The vaccine has been shown to be effective in
preventing and/or reducing the severity of RSV
infections and the number of
hospitalizations each year.
Infants who are a product of multiple births, have lung disease, low birth weight, heart disease, and those born prematurely are at a higher risk to contract a serious form of Resipritory Syncytial Virus.